SciTech Development Awarded Foundation Grant for Patented ST-001 NanoFenretinide Technology

GROSSE POINTE, Mich. - Sept. 5, 2019 - PRLog -- SciTech Development, a clinical stage drug development company, is pleased to announce that it has recently been awarded a foundation grant from a major, well-known cancer foundation for the scale-up, preparation and initiation of a Phase 1 clinical trial of ST-001 nanoFenretinide for the treatment of T-cell non-Hodgkin's lymphoma (NHL). SciTech is currently seeking a Series A equity raise of ~$15MM to bring its lead product ST-001 nanoFenretinide to market for the treatment of NHL and small cell lung cancer (SCLC).

SciTech's lead compound ST-001 nanoFenretinide is a small-molecule oncology drug employing a nanoparticle suspension for intravenous administration. ST-001 nanoFenretinide is comprised of fenretinide in a patented combination with carefully selected non-toxic phospholipids. SciTech's product pipeline includes treatment for several other cancer indications. SciTech has submitted an IND Application for ST-001 treatment of NHL. The FDA has granted Orphan Drug Status for ST-001 nanoFenretinide for the treatment of two types of NHL: peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).

Information regarding investment & partnering opportunities are available by calling Earle Holsapple at (313) 938-5517.

About SciTech Development

SciTech Development, LLC is a clinical stage, pharmaceutical company headquartered in the Metropolitan Detroit Michigan Area with laboratories at the Sinai Hospital BioIncubator in Baltimore Maryland. More information regarding SciTech's nano-delivery technology and oncology drug products are available at https://www.scitechdevelopment.com/

Forward-Looking Information

This press release and linked information contains forward-looking statements, including information about management's view of SciTech Development LLC ("the Company"), future expectations, plans and prospects. In particular, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this release and linked information other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this press release and linked information are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by SciTech Development LLC.